Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Cash & Equivalents (2016 - 2026)

Champions Oncology (CSBR) has 16 years of Cash & Equivalents data on record, last reported at $8.5 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 209.22% year-over-year to $8.5 million; the TTM value through Oct 2025 reached $8.5 million, up 209.22%, while the annual FY2025 figure was $9.8 million, 273.76% up from the prior year.
  • Cash & Equivalents reached $8.5 million in Q4 2025 per CSBR's latest filing, down from $10.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $10.3 million in Q3 2025 and bottomed at $2.6 million in Q2 2024.
  • Average Cash & Equivalents over 5 years is $5.9 million, with a median of $4.9 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: plummeted 49.93% in 2024, then surged 273.76% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $4.8 million in 2021, then surged by 67.88% to $8.1 million in 2022, then tumbled by 31.74% to $5.5 million in 2023, then plummeted by 49.93% to $2.8 million in 2024, then skyrocketed by 209.22% to $8.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $8.5 million in Q4 2025, $10.3 million in Q3 2025, and $9.8 million in Q2 2025.